Engineering therapeutic super-competitor cells for educative cancer treatment and ecological replacement

Conventional cancer therapy has largely been organized around maximal cytotoxic elimination, yet intense tumor killing can impose evolutionary selection pressures that promote resistance, clonal escape, and relapse. Here, we propose therapeutic super-competitor cells (TSCs) as a programmable, evolution-aware extension of educative cancer care rather than as an established clinical platform. In this framework, TSCs are engineered cells designed to home to or be locally positioned within tumor-associated niches, sense malignant ecological cues, transiently acquire bounded competitive fitness, restrict malignant access to space, metabolites, and stromal support, and then undergo monitored clearance or benign differentiation. TSCs are therefore not defined by direct target-cell cytolysis, although competitive pressure, metabolic restriction, or immune remodeling may secondarily reduce tumor viability. This Review integrates concepts from cancer ecology, tumor microenvironment biology, developmental cell competition, immunotherapy, and synthetic biology while distinguishing established principles from speculative engineering applications, evaluating feasible early disease contexts, and outlining measurable endpoints for ecological replacement, including spatial occupancy, clonal displacement, resource gradients, persistence kinetics, and responsiveness to safety triggers. We further discuss organoid and tumor-on-chip competition assays, spatial and lineage tracking, response biomarkers, therapeutic-window definition, layered containment, and ethical/regulatory safeguards. By reframing engineered cell therapy as a controllable ecological intervention rather than simply a vehicle for maximal killing, the TSC framework provides a testable but still hypothetical direction for educative cancer care and evolution-aware oncology.